Literature DB >> 7838007

Lactulose--a potential drug for the treatment of inflammatory bowel disease.

W Liao1, X S Cui, X Y Jin, C H Florén.   

Abstract

Lactulose is a drug mainly used as a laxative and for the treatment of porto-systemic encephalopathy. Following oral administration, intact lactulose reaches the colon, where it is split by bacteria, leading to a reduction in faecal pH and creating intestinal conditions beneficial to Lactobacillus acidophilus and inhibitory to coliform bacteria, bacteroides, Salmonella and Shigella. It was shown that lactulose therapy clears faecal salmonella and shigella species and reduces the prevalence of urinary-tract infection and respiratory tract infections. Oral administration of lactulose abolishes and prevents systemic endotoxemia of gut origin. Therefore lactulose may be used for treatment of inflammatory bowel disease as bacteria and bacterial endotoxin have an important role in the pathogenesis of this disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7838007     DOI: 10.1016/0306-9877(94)90072-8

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  9 in total

1.  Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease.

Authors:  C Favier; C Neut; C Mizon; A Cortot; J F Colombel; J Mizon
Journal:  Dig Dis Sci       Date:  1997-04       Impact factor: 3.199

2.  Increasing the intestinal resistance of rats to the invasive pathogen Salmonella enteritidis: additive effects of dietary lactulose and calcium.

Authors:  I M Bovee-Oudenhoven; D S Termont; P J Heidt; R Van der Meer
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

3.  Improved parameters of lactose maldigestion using lactulose.

Authors:  A Szilagyi; J Rivard; K Fokeeff
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

4.  Intestinal permeability.

Authors:  K R Gardiner; R J Maxwell; B J Rowlands; G R Barclay
Journal:  Gut       Date:  1995-10       Impact factor: 23.059

5.  Modification of colonic fermentation by bifidobacteria and pH in vitro. Impact on lactose metabolism, short-chain fatty acid, and lactate production.

Authors:  T Jiang; D A Savaiano
Journal:  Dig Dis Sci       Date:  1997-11       Impact factor: 3.199

6.  Diminished efficacy of colonic adaptation to lactulose occurs in patients with inflammatory bowel disease in remission.

Authors:  Andrew Szilagyi; Julie Rivard; Ian Shrier
Journal:  Dig Dis Sci       Date:  2002-12       Impact factor: 3.199

7.  Newer insights into the mechanism of action of Psidium guajava L. leaves in infectious diarrhoea.

Authors:  Tannaz Birdi; Poonam Daswani; S Brijesh; Pundarikakshudu Tetali; Arvind Natu; Noshir Antia
Journal:  BMC Complement Altern Med       Date:  2010-06-28       Impact factor: 3.659

8.  Studies on the antidiarrhoeal activity of Aegle marmelos unripe fruit: validating its traditional usage.

Authors:  S Brijesh; Poonam Daswani; Pundarikakshudu Tetali; Noshir Antia; Tannaz Birdi
Journal:  BMC Complement Altern Med       Date:  2009-11-23       Impact factor: 3.659

9.  Assessment of the pharmacokinetics, removal rate of hemodialysis, and safety of lactulose in hemodialysis patients.

Authors:  Cheng-Jui Lin; Chi-Feng Pan; Sy-Yeuan Ju; Hsuan-Kai Tzeng; Shen-Wei Chen; Jhu-Ting Syu; Chih-Jen Wu
Journal:  J Food Drug Anal       Date:  2016-08-29       Impact factor: 6.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.